🇺🇸 FDA
Pipeline program

Allogenic expanded Natural Killer Cells (AlloNK1)

2024-2264

Phase 2 mab active

Quick answer

Allogenic expanded Natural Killer Cells (AlloNK1) for Nasopharyngeal Carcinoma (NPC) is a Phase 2 program (mab) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Nasopharyngeal Carcinoma (NPC)
Phase
Phase 2
Modality
mab
Status
active

Clinical trials